Who We Are

About P4ADNOW

Patients For Affordable Drugs Now is a bipartisan national patient organization fighting to lower drug prices.

WHAT IS PATIENTS FOR AFFORDABLE DRUGS NOW?

Patients For Affordable Drugs Now is a bipartisan national patient organization focused exclusively on policies to lower drug prices. We help educate and mobilize patients in support of legislation to fix our broken system. To maintain our independence, we do not accept donations from organizations that profit from the development or distribution of prescription drugs. Touted by The Hill as “a leading drug pricing advocacy group,” Patients For Affordable Drugs Now helps patients share their drug pricing stories and ensure lawmakers are listening.

WHAT DOES PATIENTS FOR AFFORDABLE DRUGS NOW DO?

Patients For Affordable Drugs Now works at the community, state, and federal levels. We help mobilize patients to support legislation to lower drug prices across the country and engage in electoral campaigns to elevate the issue of high drug prices in political debate.

In fighting for change, we recognize that communities of color are more likely to face high prescription drug prices associated with diseases like cancer, diabetes, and asthma. As an organization dedicated to lowering drug prices, we cannot ignore the fact that racism is an insidious, systemic force that touches every part of our society, including drug pricing. We refuse to accept that status quo. We are fighting to fix the broken system. 

Where does Patients For Affordable Drugs Now get its funding?

Patients For Affordable Drugs Now — a 501(c)(4) organization — had 2018 revenue of $935,000 from the Action Now Initiative (ANI) which is funded by Laura and John Arnold.

You can view our 2019 990 form here.
You can view our 2018 990 form here.
You can view our 2017 990 form here.

Who runs P4ADNOW?

Patients For Affordable Drugs Now is governed by a bipartisan Board of Directors consisting of patients and experts in health care and communications. They are:

David Mitchell, Founder. David has an incurable blood cancer called multiple myeloma. His current drugs cost almost $875,000 per year. After more than 30 years at a Washington, D.C. policy and communications firm, he retired in 2016 to devote his full energy to helping fix our broken drug pricing system.

Ben Wakana, President. Ben served as the Deputy Assistant Secretary for Public Affairs at the U.S. Department of Health and Human Services under President Obama. He also spent time as a Communications Director on Capitol Hill and on the Obama 2012 Presidential campaign.

Robert Jones, Board Member. Before joining GS Strategy Group in Boise, Robert worked for two cycles at the National Republican Congressional Committee as the West Regional Political Director in 2014 and as the Deputy Director of the Patriot Program in 2012.

Gloria Johnson-Cusack, Board Member. Gloria is a breast cancer survivor of nearly 20 years. Currently, she is an adjunct faculty member at the School of Professional Studies at Columbia University and Chairman of the Board of Trustees of the Silicon Valley based Firelight Foundation.